Display options
Cite
Wallis C, Cheung D, Klotz L, et al. Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Can Urol Assoc J. 2017;12(2):E59-E63doi: 10.5489/cuaj.4736.
Wallis, C., Cheung, D., Klotz, L., Chalasani, V., Leao, R., Garisto, J., Morton, G., Nam, R., Tannock, I., & Satkunasivam, R. (2018). Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(2), E59-E63. https://doi.org/10.5489/cuaj.4736
Wallis, Christopher, et al. "Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,2 (2018): E59-E63. doi: https://doi.org/10.5489/cuaj.4736
Wallis C, Cheung D, Klotz L, Chalasani V, Leao R, Garisto J, Morton G, Nam R, Tannock I, Satkunasivam R. Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Can Urol Assoc J. 2018 Feb;12(2):E59-E63. doi: 10.5489/cuaj.4736. Epub 2017 Dec 01. PMID: 29381460; PMCID: PMC5937408.
Copy Download .nbib Format: NLM
Share it on

Can Urol Assoc J. 2018 Feb;12(2):E59-E63. doi: 10.5489/cuaj.4736. Epub 2017 Dec 01.

Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Christopher Wallis, Douglas Cheung, Laurence Klotz, Venu Chalasani, Ricardo Leao, Juan Garisto, Gerard Morton, Robert Nam, Ian Tannock, Raj Satkunasivam

Affiliations

  1. Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  2. Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  3. Department of Surgery, University of Sydney, Sydney, Australia.
  4. Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  5. Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

PMID: 29381460 PMCID: PMC5937408 DOI: 10.5489/cuaj.4736

Abstract

INTRODUCTION: We aimed to determine the personal practices of urologists, radiation oncologists, and medical oncologists regarding prostate cancer screening and treatment using the physician surrogate method, which seeks to identify acceptable healthcare interventions by ascertaining interventions physicians select for themselves.

METHODS: A hierarchical, contingent survey was developed through a consensus involving urologists, medical oncologists, and radiation oncologists. It was piloted at the University of Toronto and then circulated to urologists, radiation oncologists, and medical oncologists through professional medical societies in the U.S., Canada, Central and South America, Australia, and New Zealand. The primary outcome was physicians' personal choices regarding prostate-specific antigen (PSA) screening and the secondary outcome was treatment selection among those diagnosed with prostate cancer.

RESULTS: A total of 869 respondents provided consent and completed the survey. Of these, there were 719 urologists, 89 radiation oncologists, nine medical oncologists, and 53 undisclosed specialists. Most (784 of 869 respondents; 90%) endorsed past or future screening for themselves (among male physicians) or for relatives (among female physicians). Among urologists and radiation oncologists making prostate cancer treatment decisions, there was a significant correlation between physician specialty and the treatment selected (Phi coefficient=0.61; p=0.001).

CONCLUSIONS: Physicians who routinely treat prostate cancer are likely to undertake prostate cancer screening themselves or recommend it for immediate family members. Treatment choice is influenced by the well-recognized specialty bias.

References

  1. BJU Int. 2014 May;113(5b):E106-11 - PubMed
  2. J Clin Oncol. 1988 Nov;6(11):1736-45 - PubMed
  3. Ann Intern Med. 2012 Jul 17;157(2):120-34 - PubMed
  4. J Urol. 2013 Aug;190(2):419-26 - PubMed
  5. CMAJ. 2014 Nov 4;186(16):1225-34 - PubMed
  6. JAMA. 2000 Jun 28;283(24):3217-22 - PubMed
  7. Med Decis Making. 2017 Jan;37(1):56-69 - PubMed
  8. Can Fam Physician. 2010 Sep;56(9):e338-44 - PubMed
  9. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):149-54 - PubMed
  10. Br J Cancer. 1986 Oct;54(4):661-7 - PubMed
  11. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):163-9 - PubMed
  12. Arch Intern Med. 2011 Apr 11;171(7):630-4 - PubMed

Publication Types